
Sign up to save your podcasts
Or
In part two of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss the preclinical data and epidemiological data that led us to the phase three study on exenatide.
Show reference:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00161-8/abstract
4.8
129129 ratings
In part two of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss the preclinical data and epidemiological data that led us to the phase three study on exenatide.
Show reference:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00161-8/abstract
131 Listeners
288 Listeners
324 Listeners
46 Listeners
493 Listeners
14 Listeners
87 Listeners
21 Listeners
186 Listeners
343 Listeners
513 Listeners
348 Listeners
182 Listeners
366 Listeners
77 Listeners